NASDAQ:DCPH • US24344T1016
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for DECIPHERA PHARMACEUTICALS IN (DCPH).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-04-30 | Guggenheim | Downgrade | Buy -> Neutral |
| 2024-04-30 | JMP Securities | Downgrade | Market Outperform -> Market Perform |
| 2024-04-30 | Barclays | Upgrade | Underweight -> Equal-Weight |
| 2024-04-29 | JonesTrading | Downgrade | Buy -> Hold |
| 2024-04-29 | Jefferies | Downgrade | Buy -> Hold |
| 2024-03-20 | JP Morgan | Maintains | Neutral -> Neutral |
| 2024-02-07 | Stifel | Maintains | Buy -> Buy |
| 2023-11-20 | JP Morgan | Reiterate | Neutral |
| 2023-10-31 | JonesTrading | Upgrade | Hold -> Buy |
| 2023-10-31 | Stifel | Maintains | Buy -> Buy |
| 2023-10-31 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-10-30 | Piper Sandler | Upgrade | Neutral -> Overweight |
| 2023-08-10 | Stifel | Upgrade | Hold -> Buy |
| 2023-08-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-06-05 | JMP Securities | Reiterate | Market Outperform |
| 2023-05-04 | JMP Securities | Reiterate | Market Outperform |
| 2023-03-15 | JMP Securities | Reiterate | Market Outperform |
| 2023-02-08 | SVB Leerink | Reiterate | Outperform |
| 2023-02-08 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-02-07 | SVB Leerink | Maintains | Outperform |
| 2023-01-25 | Cowen & Co. | Maintains | Outperform |
| 2023-01-06 | JonesTrading | Upgrade | Sell -> Hold |
| 2023-01-04 | Guggenheim | Upgrade | Neutral -> Buy |
| 2023-01-04 | SVB Leerink | Maintains | Outperform |
| 2023-01-04 | Barclays | Maintains | Underweight |
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 96.148M 128.45% | 134.036M 39.41% | 163.356M 21.87% | 205.66M 25.90% | 264.6M 28.66% | 382.46M 44.54% | 434.31M 13.56% | 509.33M 17.27% | 610.88M 19.94% | 715.74M 17.17% | 1.039B 45.16% | |
| EBITDA YoY % growth | -297.063M -10.48% | -179.776M 39.48% | -208.858M -16.18% | -206.04M 1.35% | -208.08M -0.99% | -184.62M 11.27% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -300.077M -10.65% | -182.722M 39.11% | -210.958M -15.45% | -203.205M 3.68% | -168.305M 17.17% | -73.214M 56.50% | -25.102M 65.71% | 53.931M 314.85% | 157.78M 192.56% | 267.94M 69.82% | 538.56M 101.00% | |
| Operating Margin | -312.10% | -136.32% | -129.14% | -98.81% | -63.61% | -19.14% | -5.78% | 10.59% | 25.83% | 37.44% | 51.83% | |
| EPS YoY % growth | -5.15 -7.52% | -2.55 50.49% | -2.29 10.20% | -2.17 5.08% | -1.59 27.06% | -0.59 63.05% | -0.45 23.82% | 0.71 258.29% | 1.58 123.83% | 2.60 64.52% | 4.04 55.29% |
All data in USD
| Q2 / 24 | Q3 / 24 | Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.52 9.33% | -0.53 9.15% | -0.55 -1.16% | -0.47 9.77% | -0.44 15.13% | -0.33 38.06% | -0.08 85.06% |
| Revenue Q2Q % growth | 50.622M 32.16% | 53.839M 24.30% | 54.858M 13.59% | 49.556M 16.47% | 55.699M 10.03% | 68.122M 26.53% | 89.5M 63.15% |
| EBITDA Q2Q % growth | -49.98M 3.13% | -51M 2.01% | -54.06M -10.02% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -49.106M 6.95% | -49.524M 7.76% | -52.484M -2.43% | -49.558M -1.45% | -46.642M 5.02% | -35.814M 27.68% | -12.61M 75.97% |
All data in USD
16 analysts have analysed DCPH and the average price target is 27.25 USD. This implies a price increase of 6.47% is expected in the next year compared to the current price of 25.59.
DECIPHERA PHARMACEUTICALS IN (DCPH) will report earnings on 2024-08-07, before the market open.
The consensus EPS estimate for the next earnings of DECIPHERA PHARMACEUTICALS IN (DCPH) is -0.52 USD and the consensus revenue estimate is 50.62M USD.
The expected long term growth rate for DECIPHERA PHARMACEUTICALS IN (DCPH) is 32.58%.